nobelbiocare.com

Upwards

Enhancing the experienceand on the riseInnovation is
our passion

but it’s your reality
THAT DRIVES US.

creos™ is the Nobel Biocare regenerative product portfolio,
built to meet your everyday needs. Join us and experience
the carefully designed, easy-to-use, effective solutions.
We aim to be the trusted regenerative partner for you
and your patients, because you are what we stand for.

Sideways to your side

creos™ xenoprotect
A membrane withoutstanding handling thatfacilitates bone gain

Outstanding handling1,2‒ Does not stick to instruments‒ Repositioning in-situ possible‒ Low surface expansion
when hydrated‒ Both sides can face the defectHigh mechanical strength2,3,4‒ Excellent suture retention‒ Highly tear-resistantEnduring resistance todegradation in vivo*3‒ Manufacturing processintended to preserve the natural
structure of the collagen fiber
network, to confer a highresistance to degradation

Facilitates bone gain2,3,5,6,7,8“What I like is that the handling is veryeasy. The mechanical stability is very
high and when it is rehydrated it adapts
very well to the underlying bone”
Dr. Bastian Wessing, Germany‒ Excellent tissue compatibility3‒ Good clinical results5* As shown in an animal model (rat, subcutaneous)

PorcineHigh mechanical strength
In an in vitro study aiming to compare themechanical strength of commonly used native
non-chemically cross-linked and chemicallycross-linked collagen membranes4.
‒ creos™ xenoprotect demonstrated thehighest force at break, wet (21.2 N).
‒ creos™ xenoprotect had the highest
suture retention, wet (6.1 N).

Enduring resistance todegradation in vivo withoutchemical cross linking3
Manufacturing process intended to preserve thenatural structure of the collagen fiber network,
to confer a high resistance to degradation.3
In an animal model, after 20 weeks, the thicknessof xenoprotect decreased only slightly, whereas
the reference membrane showed a thickness lossof around 50%, confirming the higher stabilityof xenoprotect against biodegradation in vivo.3

Comparison of commercial membrane in a hydrated state30
25

Force atbreak
wet [N]

20
15
10
5

creos™ CO

JS

OF

BG

BE

ML

OP

BM

CY

Sutureretention
wet [N]creos™ CO

JS

OF

BG

BE

ML

OP

BM

CY

Non cross-linked collagen membranes (NXL) – CX: creos™ xenoprotect[Nobel Biocare]; CO: Copios [Zimmer]; JS: Jason [botiss]; OF: Osseoguard
Flex [3i]; BG: Bio-Gide [Geistlich]

20 weeks

8
7
6
5
4
3
2
1
0

20 weeks

0

Representative histological images at 20
weeks implantation in a rat model.

200 µm200 µmcreos™ xenoprotect

Reference membrane

Cross-linked collagen membranes (XL) – BE: BioMend Extend [Zimmer];
ML: Mem-Lok [BioHorizons]; OP: OssixPlus [Datum Dental]; BM: BioMend[Zimmer]; CY: Cytoplast RTM [Osteogenics]*Statistically significant

Facilitates new bone formation2,3,5,6,7,8
New bone formation (%)

In a randomized controlled clinical trial, 24
patients were treated with creos™ xenoprotect
and 25 with a reference membrane. In thecreos™ xenoprotect group, the defect height
reduced at 6-month re-entry by 81%.

4030

34.9%*

20
15.5%

10
0

creos™
xenoprotect

Reference

In a comparative in vivo study, creos™ xenoprotect
demonstrated significantly higher new boneformation in the central portion of the defect.
This increase in bone formation was associated withsignificantly increased expression of the growth factor
Bmp2, which has a strong role in osteogenesis.7

In the reference membrane group, the defectheight reduced at 6-month re-entry by 62%.5
Schematic showing the defect height prior
to treatment and 6 months after GBR
5.1 ± 2.1 mm

4.9 ± 1.9 mm

creos™ xenoprotect

Reference

1.0 ± 1.3 mm*Statistically significant

creos™ xenoprotect

1.7 ± 2.1 mm

Reference
Scan the code forclinical resources.

creos™ xenogain
3 methods of application
to meet all your bone
grafting needs

Regenerating bonefor 15 years

Three different methods of application:

Vial

Bowl

Syringe

Similar to human bone
‒ Chemical composition: Ca/P ratio‒ Interconnected macropores9,10Easy handling‒ Homogenous particle size9‒ Hydrophilic for fast rehydration11,12

Solid foundation for dental
implant treatment“I appreciated its handling properties
and I see its high hydrophilicity as a
biological advantage in sinus graftingand peri-implant defect regeneration”
Dr. Werner Zechner, Austria‒ Osteoconductive properties10‒ Long-term volume stability13
Bovine‒ Uneventful healing8,11,12,13,14

creos™ xenogain collagen
Purified cancellous bovine bone mineral granules and 10%
porcine collagen in block form and syringe. The collagenhelps to hold creos™ xenogain collagen in the desired place.
Especially recommended for extraction socket management.
Block

Syringe

BovinePorcineScaffold for successful
regeneration
Preserved natural features of bone throughoptimized manufacturing process.10

Calcium Phosphate Ratio

Chemical composition

1.5

With a calcium phosphate ratio that reflects thecomposition in human bone and a structure withlow crystallinity. The body accepts creos™ xenogain
as a suitable framework for bone formation.9

2.0
1.679

1.680

creos™ xenogain

Human bone

1.0
0.5
0.0

Particle size
‒ Homogenous particle size9‒ Maintains space for bone regeneration12
Preserved Nanostructure
Nanostructure preserved thanks to treatment at comparatively low temperature (600°C) and no sintering.10

Photographic micrograph of creos™ xenogain and reference productshowing the particle size distribution (magnification 20x)

Macro and micro-structureInterconnected macropores allow cells to
invade bone grafts and micropores contributeto capillary liquid uptake (hydrophilicity).15,16

1.0 mm

1.0 mmcreos™ xenogain(0.2 - 1.0 mm)

Reference product(0.25 – 1.0 mm)

Solid foundation for
implant placement
The graft integrates with the newly formed bone,building a basis for successful implant placement.12

Schematic showing the defect and bone size prior to and after GBR

Histological cross section of the cellular components; NB –new bone, XG – graft, scale bar shown in the bottom rightcorner, red dashed line: bone to graft particle contact.
XG+56.9%(+4 mm)

XG

XG

XG

XG

XG
435x
XG
Initial situation before GBR

8 months post-surgery
XG

In a multicenter clinical study involving 46 patients,
bone increase after 8 months was 4.0 mm (+56.9% gain) and 4.7 mm (51.0 % gain) at 1 and 3
mm from the top of the crest, respectively.8

NB

XG

NB

100 µmNB

Histological assessment of the trephinecores showed 37.3 % of new bone, 39.1
% of graft material, and 23.6 % of soft
tissue (n = 6 cores, 3 patients).8

GBR led to robust bone regeneration during
the 8 months of healing, enabling successfulplacement of 91 implants in 43 patients, with anaverage insertion torque of 37.8 ± 5.1 Ncm.8
Scan the code forclinical resources.

creos™ allo.gain& allo.protect
A wide range of allograft
materials, because all yourcases are different

Broad allograft
portfolio for different
clinical indications*‒ Mineralized and demineralized‒ Cortical and cancellous‒ Available in a bowl foran easy handlingallo.gain demineralizedbone matrix (dbm) putty‒ 100% pure demineralized allograft with nofiller or inert carrier‒ Syringe type dispenser
for easy application

allo.protect pericardium
membrane‒ Durable protection

Ensuring safety and quality levels‒ A proprietary patented process of tissue cleaning and sterilization‒ The tissue bank follows strict processing procedures in order to ensure
safe tissue grafts of the highest quality for transplantation*See Instructions For Use for full prescribing information, including
indications, contraindications, warnings and precautions

Allograftcreos™ allo.gain bone particulate:a wide range of options

100 µm / 435x
Mineralized cancellous boneMineralized cortical boneMineralized cancellous bone

Offers a high density bone withparticle size range from 0.125
mm to 1 mm and available
volume of 0.25 cc to 2.0 cc.

A porous structured bone withparticle size range from 0.25
mm to 1 mm and available
volume of 0.25 cc to 2.0 cc.

Mineralized/demineralized
cortical bone

Demineralized cortical bone

Blend of 70% mineralized and
30% demineralized cortical bone.
Mineralized corticocancellous bone

Demineralized high density bonewith particle size range from0.125 mm to 1 mm and available
volume of 0.25 cc to 2.0 cc.

Blend of cortical andcancellous bone produced
from sections of the ilium.

creos™ allo.gain demineralizedbone matrix (dbm) putty
100% pure allograft

Available in Three volumes

The creos™ allo.gain dbm putty is
100% pure demineralized allograftwith no filler or inert carrier.

The creos™ allo.gain dbm putty isavailable in three different volumes:
0.5 cc, 1.0 cc and 2.5 cc. This meansthat the required amount can beused with minimal excess material.

Three sizes

Durable protection

creos™ allo.protect is available inthree different sizes: 1.0 x 1.0 cm,
1.5 x 2.0 cm and 2.0 x 3.0 cm.

Strong and stable due to the pore
structuwre of native pericardium.

100 µm / 85x

creos™ allo.protect
pericardium membrane

Easy to handle

2 µm / 10,000x

Easy to tack and suture with hightear resistance. Rapid hydrationand easy manipulation. Maintains
shape and size once placed.

Biocompatible and tissue friendly
Preservation of the native
pericardium collagen matrix
and its mechanical properties.

Scan the code forclinical resources.

creos™ syntoprotect
Your easy choice of dense
PTFE membranes toexpand grafting options

syntoprotect
PTFE membrane
Purposely leave themembrane exposed
Preservation of the soft tissue architecture and keratinized mucosa

100% dense (non-expanded) PTFE
Impervious to bacteria - poresize less than 0.3 µm

Non-resorbable

Soft tissue attaches, but doesn’t
grow through the membrane

Will not resorb prematurely you dictate healing time

Exposed membrane allows for non-surgical removal; no anesthesia required

Synthetic

syntoprotect
Ti-reinforced
PTFE membrane
Delicate, lightweight framework

Handling options

Easy to trim and compliant withthe overlying soft tissues

Broad portfolio with 13
shapes in 2 thicknesses

Less is more

Traditional frame design

Less titanium bulk allows for greater
versatility in shaping and placement,
providing additional stability in large,
non-spacemaking osseous defects

Incorporating delicate and strategically-placed titanium “struts”
with more than 25 years of clinicalhistory and successful use in GRB

Unique properties of dense PTFE membranes
Dense PTFE

Expanded PTFE

20 µm

20 µm

SEM image courtesy of Schüpbach Ltd, Switzerland.

SEM image courtesy of Schüpbach Ltd, Switzerland.

Dense PTFE was designed towithstand exposure in the oral
environment, which represents an
improvement to earlier versionsof expanded PTFE in applications
such as socket preservation where
deliberate membrane exposure
offers several advantages.

Designed to aid in membrane stabilization

200 µmAlthough PTFE isinherently a non-stickmaterial, cells attach
to the outside of thedense PTFE membranes.
Cellular adhesion isimportant to create aseal around the edgesof exposed dense PTFE
membranes or to support
primary closure in larger
graft applications.

Hexagonal surface
dimples provide a
textured surface that
increases the area
available for cellular
attachment without
increasing porosity.
The textured surface isdesigned to help stabilize
the membrane andthe soft tissue flap.

SEM image courtesy of SchüpbachLtd, Switzerland.

Clinical evidence
Efficacy
Bone loss 1-year post-extraction19

Soft tissue regeneration 90
days post-extraction20

Vertical ridge augmentation around implants21

1.5

100%

6

N=12

5

5.49 mm

1.0

0.5

0

N=15

4

59.68%

3

N=10

N=15

0.25 mm0.30 mm

VerticalBone Loss

Horizontal
Bone Loss

Vertical bone loss measured at crest. Horizontal
measured from stent to buccal plate.

18.25%
0%syntoprotect PTFE No Membrane
membrane

Measured as reduction of the occlusal distance
between buccal and lingual gingival margins.

N=11
4.91 mm2
1
0syntoprotect
Ti-reinforced
PTFE membrane

Expanded PTFE

Mean vertical bone regeneration.

Predictability
In two separate studies treating a total of 696 extraction
sites using dense PTFE membranes in an exposed
technique, there were no reported infections.17,18

Scan the code forclinical resources.

creos™ absorbablecollagen dental
wound dressings
Complementing yourregenerative set

Three different shapes

creos™ xenotape
creos™ xenoplug
creos™ xenocote

Soft, white, pliable, non-friable, absorbent
sponges made from collagen obtained frombovine deep flexor (Achilles) tendons.
Indicated for application to moist or bleedingclean oral wounds created during dental
surgery, to control bleeding and protect thesurface of the wound from further injury.
Can be used during surgical procedures
prior to wound closure or left in-situ.

BovineDepending on the chosen wounddressings product, one or more of thefollowing applications are suitable*:‒ Minor oral wounds‒ Closure of grafted sites‒ Repair of Schneiderian membrane‒ Palatal donor sites‒ Mucosal flaps‒ Extraction sites‒ Biopsy sites*See Instructions For Use for full prescribing information, including indications,contraindications, warnings and precautions.

Arrive ready to use and are easy to handle.

Scan the code formore resources.

Products
creos™ xenoprotect
Porcine collagen membrane

Size

Article No.

15x20 mmN1520

25x30 mmN2530

30x40 mmN3040

creos™ xenogain
Deproteinized bovine bone matrix

Weight0.25 g0.50 g1.00 g2.00 g

Granule size

VolumeVial

Bowl

Syringe

Small (0.2-1.0 mm)

0.36 cc

N1110

N1110-B

N1210

Large (1.0- 2.0 mm)

0.54 cc

N1111

N1111-B

N1211

Small (0.2-1.0 mm)

0.82 cc

N1120

N1120-B

N1220
N1221

Large (1.0- 2.0 mm)

1.27 cc

N1121

N1121-B

Small (0.2-1.0 mm)

1.71 cc

N1130

N1130-B

Large (1.0- 2.0 mm)

2.69 cc

N1131

N1131-B

Small (0.2-1.0 mm)

3.64 cc

N1140

N1140-B

Large (1.0- 2.0 mm)

5.74 cc

N1141

N1141-B

creos™ xenogain collagencreos™ xenogain + 10% porcine collagen type I

Size
Block

Syringe

Article No.

100 mg6 x 6 x 6 mm

N1320

250 mg7 x 8 x 9 mm

N1330

500 mg

9 x 10 x 11 mm

N1340

250 mg

4.6 x 40 mm

N1410

500 mg5.6 x 45 mm

N1420

creos™ allo.gain
bone particulate

Vial

min/demincortical

N4510

N4511

N4210

N4211

N4110

N4111

N4112

N4310

N4311

N4410

N4520

N4521

N4220

N4221

N4120

N4121

N4122

N4320

N4321

0.25-1 mm

0.5-1 mm

Mediumdemineralized
corticalmineralized cortical

Medium0.25 ccLargemineralized
cancellous

Medium0.25-1 mm

0.50 ccmineralized
corticocancellous

Large0.25-1 mm

Small

0.5-1 mm

0.125-0.85 mm

Medium0.25-1 mm

Large

0.5-1 mm

Small

0.125-0.85 mm

Large

0.5-1 mm1.00 cc

N4420

N4530

N4531

N4230

N4231

N4130

N4131

N4132

N4330

N4331

2.00 cc

N4430

N4540

N4541

N4240

N4241

N4140

N4141

N4142

N4340

N4341

Bowl

min/demincorticalmineralized
cancellous

Medium
N4510-B

N4511-B

N4210-B

N4110-B

N4111-B

N4410-B

N4520-B

N4521-B

N4220-B

N4120-B

N4121-B

0.25 ccLargemineralized
corticalMedium0.25-1 mm

0.50 ccmineralized
corticocancellous
0.25-1 mm

Medium0.5-1 mmSmall

0.25-1 mm

0.125-0.85 mm

Medium0.25-1 mm

1.00 cc

N4420-B

N4530-B

N4531-B

N4230-B

N4130-B

N4131-B

2.00 cc

N4430-B

N4540-B

N4541-B

N4240-B

N4140-B

N4141-B

creos™ allo.gain

creos™ allo.protect

dbm putty

pericardium membrane

Size

Article No.

0.50 cc

N6110

Size
10 x 10 mm

Article No.
N7110

1.00 cc

N6120

15 x 20 mm

N7120

2.50 cc

N6130

20 x 30 mm

N7140

creos™ wound dressings
Product type

Configuration/size

creos™ xenotape

1 in x 3 in

(2.5 cm x 7.5 cm)

creos™ xenoplug

0.375 in x 0.75 in(1 cm x 2 cm)

creos™ xenocote

0.75 in x 1.5 in(2 cm x 4 cm)(10 per dispenser)

Thickness

Article No.

0.3-0.8 mm

WD62200
WD62202

2-4 mm

WD62201

creos™ syntoprotect PTFE membrane
Shape

Picture

Size

Large

25 x 30 mm

Small

12 x 24 mm

Thickness

Article No.

Units / box Description

200 μm

N162530-1

1200 μm

N162530-44200 μm

N161224-1

1200 μm

N161224-10

10

Designed specifically for extraction site
grafting and augmentation procedures
where exposure to the oral cavity is common

creos™ syntoprotect Ti-reinforced PTFE membrane
Shape
No. 1
No. 2

PictureSize
12 x 24 mm

14 x 24 mm

No. 3

17 x 25 mm

No. 4

20 x 25 mm

No. 5

36 x 25 mm

No. 6

25 x 30 mm

No. 7

30 x 41 mm

No. 8

30 x 40 mm

No. 9

30 x 40 mm

No. 1024 x 38 mm

No. 1138 x 38 mm

No. 12

No. 13Thickness

Article No.

150 μm

N1615TI-A01-1

Units / box Description
1

250 μm

N1625TI-A01-1

1

150 μm

N1615TI-A02-1

1

250 μm

N1625TI-A02-1

1

150 μm

N1615TI-A03-1

1

250 μm

N1625TI-A03-1

1

150 μm

N1615TI-A04-1

1

250 μm

N1625TI-A04-1

1

150 μm

N1615TI-A05-1

1

250 μm

N1625TI-A05-1

1

150 μm

N1615TI-A06-1

1

250 μm

N1625TI-A06-1

1

150 μm

N1615TI-A07-1

1

250 μm

N1625TI-A07-1

1

150 μm

N1615TI-A08-1

1

250 μm

N1625TI-A08-1

1

150 μm

N1615TI-A09-1

1

250 μm

N1625TI-A09-1

1

150 μm

N1615TI-A10-1

1

250 μm

N1625TI-A10-1

1

150 μm

N1615TI-A11-1

1

250 μm

N1625TI-A11-1

1

150 μm

N1615TI-A12-1

1

250 μm

N1625TI-A12-1

1

150 μm

N1615TI-A13-1

1

250 μm

N1625TI-A13-1

1

38 x 38 mm

40 x 50 mm

Designed for narrow single-tooth
extraction sites, especially where
one bony wall is missing
Designed for single-tooth extraction
sites, especially where one ormore bony walls are missing
Designed for large buccal defects
Designed for large extraction sites
and limited ridge augmentation
Designed for large extraction sites
and limited ridge augmentationin the anterior maxilla
Designed for large bony defects,
including ridge augmentation

Designed for large bony defects, including
ridge augmentation in the anterior maxilla

Designed for very large bony defects,
including ridge augmentation

Designed for very large bony defects,
including ridge augmentation

Designed for large extraction sites,
including ridge augmentation

Designed for large bony defects,
including ridge augmentation

Designed for large bony defects, including
distal extension of the posterior ridge

Designed for the largest bony defects,
including ridge augmentation

References
1-10

11-20

1. Arrighi I, Wessing B, Rieben A, et al.
Resorbable collagen membranes expansion invitro. J Dent Res 2014;93 (Spec Iss B):631

11. Park HN, Han, SH, Kim KW, et al. A study
on the safety and efficacy of bovine bonederived bone graft material (OCS-B). J Korean
Acad Periodontol. 2005 Jun;35(2):335 – 43

2. Wessing B, Emmerich M, Bozkurt A. Horizontal
ridge augmentation with a novel resorbablecollagen membrane: a retrospective analysis
of 36 consecutive patients. Int J Periodontics
Restorative Dent 2016;36(2):179–187.

12. Park JB, et al. Maxillary sinus floor augmentation using deproteinized bovine bone-derived bone
graft material (OCS-B). Clinical and histologic
findings in humans. The Journal of the Korean
Dental Association. 2007;45(8):491–99

3. Bozkurt A, Apel C, Sellhaus B, et al. Differencesin degradation behavior of two non-cross-linked
collagen barrier membranes: an in vitro and in vivo
study. Clin Oral Impl Res; 2014; 25(12):1403-1411

13. Shin S-Y, et al. Long-term results of new deproteinized bovine bone material in a maxillary sinus graft
procedure. J Periodontal Implant Sci. 2014;44;259-64.

4. Gasser A, Wessing B, Eummelen L, et al.
Mechanical stability of collagen membranes: an invitro study. J Dent Res 2016;95(Spec Iss A): 1683

14. Kim Y-T, et.al. Periodontal Repair on Intrabony Defects
treated with Anorganic Bovine-derived Xenograft.J
Korean Acad Periodontol. 2007;37(3):489 – 96

5. Wessing B, Urban I, Montero E, et al. A multicenter
randomized controlled clinical trial using a newresorbable non-cross- linked collagen membrane
for guided bone regeneration at dehisced single
implant sites: interim results of a bone augmentation
procedure. Clin Oral Impl Res; 2017;28(11):e218–e226.

15. Fernandez de Grado G, Keller L, Idoux-Gillet Y et al.
Bone substitutes: a review of their characteristics, clinicaluse, and perspectives for large bone defects management.
Journal of Tissue Engineering Volume 9: 1–18, 2018

6. Sanz-Sanchez I, Wessing B, Polizzi G, et al.
Randomized clinical trial comparing two resorbablecollagen membranes demonstrates good boneformation and soft tissue healing with GBR at
single implant sites with dehiscence defects. J Clin
Periodontol 2018;45(S19):19–20 [oral presentation].
7. Omar O, Dahlin A, Gasser A, et al. Tissue dynamics
and regenerative outcome in two resorbable noncross-linked collagen membranes for guided boneregeneration: A preclinical molecular and histological study in vivo. Clin Oral Impl Res; 2018;29(1):7–19
8. Aleksic Z, Milikovic I, Lazic Z, et al. A multicenter
clinical investigation demonstrates bone regeneration in severe horizontal defects in the posterior
mandible using creos™ xenoprotect: Interim
results. J Clin Periodontol 2018;45(S19):306
9. Nobel Biocare, data on file.
10. Rhee S-H, Park HN, Seol Y-J et al. Effect ofheat-treatment temperature on the osteoconductivity of the apatite derived from bovine bone.
2006 Key Engineering Materials 309-311:41-44

16. Zhang K , Fan Y, Dunne N et al. Effect of microporosity on scaffolds for bone tissue engineering.
Regenerative Biomaterials, 2018, 115–124
17. Barboza EP, Stutz B, Ferreira VF, Carvalho W.
Guided bone regeneration using nonexpanded polytetrafluoroethylene membranes in preparation
for dental implant placements - a report of420 cases. Implant Dent. 2010;19:2-7.
18. Hoffman O, Bartee BK, Beaumont C, Kasaj A,
Deli G, Zafiropoulos GG. Alveolar bone preservation in extraction sockets using non-resorbabledense PTFE membranes: A retrospective non-randomized study. J Periodontol 2008;79:1355-1369.
19. Fotek PD, Neiva RF, Wang HL. Comparison ofdermal matrix and polytetrafluoroethylene membrane
for socket bone augmentation: a clinical andhistologic study. J Periodontol 2009;80:776-785.
20. Barboza EP, Francisco BS, Ferreira VF. Soft tissue
enhancement using non-expanded PTFE membranes
without primary closure [abstract]. Presented atthe 2008 Research Forum Poster Session. Annual
Meeting of the American Academy of Periodontology(AAP) in Seattle, WA, September 6-9, 2008.

21
21. Ronda M, Rebaudi A, Torelli L, Stacchi C. Expanded
vs. dense polytetrafluoroethylene membranes invertical ridge augmentation around dental implants:
a prospective randomized controlled clinical trial.
Clin. Oral Impl. Res. 2014 Jul;25(7):859-66.

Order online
Order the complete creos™
range 24 hours a day throughthe Nobel Biocare online store.
store.nobelbiocare.com

Order by phone
Contact your sales representative
or call our customer service teamUS
800 322 5001
Canada 800 939 9394

nobelbiocare.com
87896 B NA 2212 (Rev 01, 12/22) Printed in USA © Nobel Biocare USA, LLC, 2022. All rights reserved.
Disclaimer: Nobel Biocare, the Nobel Biocare logotype and all other trademarks are, if nothing else is stated or is evident from the context in a certain case, trademarks ofNobel Biocare. Please refer to nobelbiocare.com/trademarks for more information. Product images are not necessarily to scale. All product images are for illustration
purposes only and may not be an exact representation of the product. Some products may not be regulatory cleared/released for sale in all markets. Please contact the
local Nobel Biocare sales office for current product assortment and availability. Caution: Federal (United States) law or the law in your jurisdiction may restrict this device
to sale by or on the order of a dentist or a physician. See Instructions For Use for full prescribing information, including indications, contraindications, warnings andprecautions. creos™ xenoprotect is manufactured by Matricel GmbH, Kaiserstrasse 100, D-52134 Herzogenrath, Germany and distributed by Nobel Biocare USA, LLC.
creos™ xenogain and creos™ xenogain collagen are manufactured by NIBEC Co., Ltd., Iwol electricity-electronic Agro-Industrial Complex, 116, Bamdi-gil, Iwol-myeon,
Jincheon-gun, Chungcheongbuk-do, 27816, Korea and distributed by Nobel Biocare USA, LLC. creos™ allo.gain and creos™ allo.protect are manufactured by Community
Tissue Services (CTS), 2900 College Drive, Kettering, OH 45420, USA and distributed by Nobel Biocare USA, LLC. creos™ syntoprotect is manufactured by Osteogenics
Biomedical, Inc., 4620 71st Street, Bldg 78-79, Lubbock, TX 79424, USA and distributed by Nobel Biocare USA, LLC. creos™ xenocote, creos™ xenotape and creos™ xenoplug
are manufactured by Integra LifeSciences Corporation, 311 Enterprise Drive, Plainsboro, NJ 08536, USA and distributed by Nobel Biocare USA, LLC.